{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:39Z","timestamp":1786985079194,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004192","name":"National Science and Technology Development Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.bcp.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T12:47:39Z","timestamp":1525697259000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion"],"prefix":"10.1016","volume":"154","author":[{"given":"Jiriporn","family":"Nantavishit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varanuj","family":"Chatsudthipong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunhapas","family":"Soodvilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2018.05.005_b0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3904\/kjim.2009.24.3.165","article-title":"Autosomal dominant polycystic kidney disease: 2009 update for internists","volume":"24","author":"Bennett","year":"2009","journal-title":"Korean J. Intern. Med."},{"issue":"1","key":"10.1016\/j.bcp.2018.05.005_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2796.2006.01743.x","article-title":"Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities","volume":"261","author":"Torres","year":"2007","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.bcp.2018.05.005_b0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1083\/jcb.201006173","article-title":"The cell biology of polycystic kidney disease","volume":"191","author":"Chapin","year":"2010","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2018.05.005_b0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases","volume":"2","author":"Torres","year":"2006","journal-title":"Nat. Clin. Pract. Nephrol."},{"issue":"11","key":"10.1016\/j.bcp.2018.05.005_b0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","article-title":"mTOR signaling in polycystic kidney disease","volume":"17","author":"Ibraghimov-Beskrovnaya","year":"2011","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.bcp.2018.05.005_b0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.molmed.2010.05.004","article-title":"Cystic kidney disease: the role of Wnt signaling","volume":"16","author":"Lancaster","year":"2010","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.bcp.2018.05.005_b0035","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.bcp.2018.05.005_b0040","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/hmg\/8.10.1861","article-title":"Autosomal dominant polycystic kidney disease: clues to pathogenesis","volume":"8","author":"Harris","year":"1999","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2018.05.005_b0045","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bbadis.2010.11.005","article-title":"Cyclic AMP-mediated cyst expansion","volume":"1812","author":"Wallace","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"Pt. 10","key":"10.1016\/j.bcp.2018.05.005_b0050","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1113\/jphysiol.2009.171595","article-title":"Gating of the CFTR Cl-channel by ATP-driven nucleotide-binding domain dimerisation","volume":"587","author":"Hwang","year":"2009","journal-title":"J. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2018.05.005_b0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1569-1993(01)00003-0","article-title":"The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions","volume":"1","author":"Vankeerberghen","year":"2002","journal-title":"J. Cyst. Fibrosis"},{"issue":"1","key":"10.1016\/j.bcp.2018.05.005_b0060","doi-asserted-by":"crossref","first-page":"c25","DOI":"10.1159\/000334166","article-title":"Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects","volume":"120","author":"Chang","year":"2012","journal-title":"Nephron Clin. Pract."},{"issue":"4","key":"10.1016\/j.bcp.2018.05.005_b0065","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2215\/CJN.05651207","article-title":"Strategies to inhibit cyst formation in ADPKD","volume":"3","author":"Calvet","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.bcp.2018.05.005_b0070","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcp.12136","article-title":"New treatments for autosomal dominant polycystic kidney disease","volume":"76","author":"Chang","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.05.005_b0075","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"301","author":"Elliott","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2018.05.005_b0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1515\/jtim-2016-0028","article-title":"Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor \u03b3 agonists","volume":"4","author":"Flaig","year":"2016","journal-title":"J. Transl. Intern. Med."},{"issue":"5","key":"10.1016\/j.bcp.2018.05.005_b0085","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","article-title":"Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model","volume":"300","author":"Leonhard","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"9","key":"10.1016\/j.bcp.2018.05.005_b0090","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1681\/ASN.2008030259","article-title":"Triptolide reduces cystogenesis in a model of ADPKD","volume":"19","author":"Leuenroth","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.bcp.2018.05.005_b0095","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ndt\/gfw058","article-title":"Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor kappaB-induced inflammation","volume":"31","author":"Wu","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.bcp.2018.05.005_b0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/phar.1421","article-title":"Review of tolvaptan for autosomal dominant polycystic kidney disease","volume":"34","author":"Baur","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"15","key":"10.1016\/j.bcp.2018.05.005_b0105","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-015-0475-x","article-title":"Tolvaptan: a review in autosomal dominant polycystic kidney disease","volume":"75","author":"Blair","year":"2015","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2018.05.005_b0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcp.2018.05.005_b0115","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.12688\/f1000research.9045.1","article-title":"Autosomal dominant polycystic kidney disease: recent advances in clinical management","volume":"5","author":"Mao","year":"2016","journal-title":"F1000Res"},{"issue":"20","key":"10.1016\/j.bcp.2018.05.005_b0120","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bcp.2018.05.005_b0125","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14656566.2.10.1663","article-title":"Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses","volume":"2","author":"Gremse","year":"2001","journal-title":"Exp. Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.bcp.2018.05.005_b0130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1368-5031.2005.00517.x","article-title":"Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases","volume":"59","author":"Robinson","year":"2005","journal-title":"Int. J. Clin. Pract."},{"issue":"7","key":"10.1016\/j.bcp.2018.05.005_b0135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14656566.6.7.1049","article-title":"Proton pump inhibitors may reduce tumour resistance","volume":"6","author":"De Milito","year":"2005","journal-title":"Exp. Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.bcp.2018.05.005_b0140","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jphp.12237","article-title":"Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects","volume":"66","author":"Hao","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2018.05.005_b0145","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bcp.2009.12.018","article-title":"Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist","volume":"79","author":"Cronican","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2018.05.005_b0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.physiol.68.033104.152158","article-title":"LXRS and FXR: the yin and yang of cholesterol and fat metabolism","volume":"68","author":"Kalaany","year":"2006","journal-title":"Annu. Rev. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2018.05.005_b0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/156720507780362227","article-title":"Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease \u2013 implications for a new therapeutic approach","volume":"4","author":"Koldamova","year":"2007","journal-title":"Curr. Alzheimer Res."},{"issue":"4","key":"10.1016\/j.bcp.2018.05.005_b0160","doi-asserted-by":"crossref","first-page":"F583","DOI":"10.1152\/ajprenal.00579.2012","article-title":"Activation of liver X receptors reduces CFTR-mediated Cl(\u2212) transport in kidney collecting duct cells","volume":"305","author":"Raksaseri","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"2 Pt B","key":"10.1016\/j.bcp.2018.05.005_b0165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.canlet.2014.10.017","article-title":"Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma","volume":"356","author":"Azzarito","year":"2015","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bcp.2018.05.005_b0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbrc.2014.04.127","article-title":"Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion","volume":"448","author":"Zhang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2018.05.005_b0175","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2018.05.005_b0180","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfx289","article-title":"Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease","author":"Chang","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.bcp.2018.05.005_b0185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mehy.2011.01.037","article-title":"Modulation of liver X receptor signaling as a prevention and therapy for colon cancer","volume":"76","author":"Chuu","year":"2011","journal-title":"Med. Hypotheses"},{"issue":"21","key":"10.1016\/j.bcp.2018.05.005_b0190","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1158\/0008-5472.CAN-04-2332","article-title":"Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells","volume":"64","author":"Fukuchi","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2018.05.005_b0195","first-page":"7676","article-title":"Liver X receptors as potential targets for cancer therapeutics","volume":"14","author":"Ju","year":"2017","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2018.05.005_b0200","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1523-1755.2001.00473.x","article-title":"The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease","volume":"59","author":"Lager","year":"2001","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.bcp.2018.05.005_b0205","doi-asserted-by":"crossref","first-page":"e0177934","DOI":"10.1371\/journal.pone.0177934","article-title":"Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease","volume":"12","author":"Kugita","year":"2017","journal-title":"PLoS One"},{"issue":"36","key":"10.1016\/j.bcp.2018.05.005_b0210","doi-asserted-by":"crossref","first-page":"28240","DOI":"10.1074\/jbc.M003337200","article-title":"Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor\/retinoid X receptor","volume":"275","author":"Costet","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.bcp.2018.05.005_b0215","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR\u03b1 and LXR\u03b2","volume":"14","author":"Repa","year":"2000","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.bcp.2018.05.005_b0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1523-1755.2003.00755.x","article-title":"Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease","volume":"63","author":"Nagao","year":"2003","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.bcp.2018.05.005_b0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ndt\/gfu296","article-title":"An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease","volume":"30","author":"Ravichandran","year":"2015","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218301904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218301904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:57:43Z","timestamp":1751605063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218301904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"alternative-id":["S0006295218301904"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.05.005","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}